Ad-hoc | 19 January 2006 15:35

Eckert & Ziegler AG: 20% Revenue Growth, Earnings Affected by Start-up Cost.

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Berlin, 19.01.2006 – Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a specialist for medical devices and components used in the diagnosis and treatment of cancer, closed its fourth quarter with record revenues of 12.3 mm EUR. Based on preliminary calculations the increase translates also in record revenues of 42.3 mm EUR for the full 2005 business year, an increase of close to 20% over the 2004 numbers (35.5 mm EUR). According to yet un-audited numbers, the Earnings before Tax and Minority interests decreased in 2005 to 2.4 mm EUR (2004: 3.6 mm EUR), mostly because of start-up cost for the new radiopharmaceutical activities. In 2006 the management team expects revenue growth to about 50 mm EUR and a return to the previous year’s earning levels. Details on the 2005 numbers and the projections for 2006 will be presented at the annual press conference in Berlin on 31 March 2006. For further questions please contact: Karolin Riehle, Investor Relations Phone: +49 (0) 30 / 94 10 84-138 www.ezag.de ECKERT & ZIEGLER Strahlen- und Medizintechnik AG Robert-Rössle-Str. 10 13125 Berlin Deutschland ISIN: DE0005659700 WKN: 565970 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart End of ad hoc announcement (c)DGAP 19.01.2006